Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer

Journal of the National Cancer Institute

Volumn 98, Issue 16, 2006, Pages 1108-1117

  Hassett, Michael J ^a   O'Malley, A James ^b   Pakes, Juliana R ^b   Newhouse, Joseph P ^b   Earle, Craig C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; GROWTH FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AMBULATORY CARE; ANEMIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG COST; DRUG FEVER; ELECTROLYTE DISTURBANCE; EMERGENCY CARE; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALNUTRITION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; BREAST TUMOR; ECONOMICS; EMERGENCY HEALTH SERVICE; HOSPITAL ADMISSION; INSURANCE; MIDDLE AGED; RISK; STATISTICAL MODEL; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; PATIENT ADMISSION; UNITED STATES;

EID: 33747400905     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj305     Document Type: Article

References (41)

1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: A clinician's guide to terminology, documentation, and reporting [see comment]. Ann Intern Med 2004;140:795-801.
2. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management [see comment]. Lancet 2000;356:1255-9.
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18820 patients [see comment]. BMJ 2004;329:15-9.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies [see comment]. JAMA 1998;279:1200-5.
5. Kohn LT, Corrigan J, Donaldson MS. To err is human; building a safer health system. Washington (DC): National Academy Press; 2000.
6. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004;22:3485-90.
7. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 2001;285:437-43.
8. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" [see comment]. Lancet 2005;365:82-93.
9. Singh D. Merck withdraws arthritis drug worldwide. BMJ 2004;329:816.
10. Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, KuZel TC, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: First results from the research on adverse drug events and reports project. [erratum in J Clin Oncol 2004;22:1169]. J Clin Oncol 2003;21:3859-66.
11. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
12. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997-2008.
13. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-42.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
15. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53: 1258-67.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9.
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
18. Joffe MM, Rosenbaum PR. Invited commentary: Propensity scores. Am J Epidemiol 1999;150:327-33.
19. Land SR, Kopec JA, Yothers G, Anderson S, Day R, Tang G, et al. Healthrelated quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 2004;86:153-64.
20. Hampson JP, Harvey JN. Postmarketing surveillance and black box warnings [comment]. JAMA 2002;288:956; author reply 958-9.
21. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005;10:198-204.
22. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomised trials: Exclusions and selective participation. J Health Serv Res Policy 1999;4:112-21.
23. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: A descriptive study of published reports [see comment]. BMJ 1997;315:1059.
24. Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D, Polk OD, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol 2004;22:730-4.
25. Gross CP, Filardo G, Mayne ST, Krumholz HM. The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer 2005;103:483-91.
26. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities [see comment]. JAMA 2004;291: 2720-6.
27. Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center [see comment]. J Clin Oncol 2004; 22:2046-52.
28. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. I Clin Oncol 2004;22:4626-31.
29. Antman K, Amato D, Wood W, Carson J, Suit H, Proppe K, et al. Selection bias in clinical trials. J Clin Oncol 1985;3:1142-7.
30. Bertelsen K. Protocol allocation and exclusion in two Danish randomised trials in ovarian cancer. Br J Cancer 1991;64:1172-6.
31. Chen Cl, Skingley P, Meyer RM. A comparison of elderly patients with aggressive histology lymphoma who were entered or not entered on to a randomized phase II trial. Leuk Lymphoma 2000;38:327-34.
32. Hjorth M, Holmberg E, Rodjer S, Westin J. Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western, Sweden. Br J Haematol 1992;80:55-61.
33. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer [see comment]. J Clin Oncol 1997; 15:3171-7.
34. Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994;70:352-62.
35. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 2001;54:217-24.
36. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review [see comment]. Lancet 2004;363:263-70.
37. Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Systematic review to determine whether participation in a trial influences outcome [see comment]. BMJ 2005;330:1175.
38. Delea TE, Vera-Llonch M, Edelsberg JS, McGarry L, Anton S, Ulcickas-Yood M, et al. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 2002;5:35-43.
39. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis [see comment]. Cancer 2003;98:1531-9.
40. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004;22:3524-30.
41. Arozullah AM, Calhoun EA, Wolf M, Finley DK, Fitzner KA, Heckinger EA, et al. The financial burden of cancer: Estimates from a study of insured women with breast cancer. J Support Oncol 2004;2:271-8.